

Supplementary table 2. Adjusted hazard ratios and confidence intervals for all-cause mortality in gastric cancer, colorectal cancer, and lung cancer patients aged 18–59 years

	Gastric cancer (n=1234)				Colorectal cancer (n=1470)				Lung cancer (n=1049)			
	n	Mortality (%)	aHR (95% CI)	P value	n	Mortality (%)	aHR (95% CI)	P value	n	Mortality (%)	aHR (95% CI)	P value
Sex												
Female	440	137 (31.1)	Reference		706	159 (22.5)	Reference		376	160 (42.6)	Reference	
Male	794	201 (25.3)	0.94 (0.75–1.16)	0.55	764	210 (27.5)	1.22 (0.99–1.50)	0.061	673	407 (60.5)	1.79 (1.48–2.16)	<0.001
Comorbidities^a												
None	1072	283 (26.4)	Reference		1263	294 (23.3)	Reference		818	429 (52.4)	Reference	
Moderate	146	49 (33.6)	1.27 (0.93–1.72)	0.131	188	68 (36.2)	1.24 (0.95–1.63)	0.115	213	130 (61.0)	1.25 (1.03–1.52)	0.027
Severe	16	6 (37.5)	0.60 (0.27–1.37)	0.23	19	7 (36.8)	1.47 (0.69–3.11)	0.32	18	8 (44.4)	1.71 (0.85–3.48)	0.135
Cancer stage												
Localized	708	13 (1.8)	Reference		643	20 (3.1)	Reference		277	23 (8.3)	Reference	
Regional	253	86 (34.0)	21.38 (11.93–38.31)	<0.001	503	100 (19.9)	7.01 (4.33–11.33)	<0.001	274	133 (48.5)	6.57 (4.22–10.25)	<0.001
Distant	273	239 (87.5)	117.79 (67.07–206.87)	<0.001	324	249 (76.9)	46.96 (29.68–74.30)	<0.001	498	411 (82.5)	19.36 (12.66–29.61)	<0.001
Tumor histology												
Non-small cell carcinoma	–	–	–	–	–	–	–	–	943	476 (50.5)	Reference	
Small cell carcinoma	–	–	–	–	–	–	–	–	106	91 (85.8)	1.47 (1.17–1.85)	0.001
Functional status^b												
No disability	1162	300 (25.8)	Reference		1365	315 (23.1)	Reference		948	485 (51.2)	Reference	
Moderate disability	51	21 (41.2)	1.47 (0.94–2.29)	0.090	70	33 (47.1)	1.76 (1.22–2.54)	0.002	53	42 (79.2)	1.91 (1.39–2.62)	<0.001
Severe disability	21	17 (81.0)	3.82 (2.32–6.30)	<0.001	35	21 (60.0)	3.14 (2.01–4.91)	<0.001	48	40 (83.3)	2.39 (1.73–3.30)	<0.001

Mortality is expressed as the number of patients (percentage of all patients at risk as indicated in the leftmost column). aHRs were calculated from Cox proportional hazards models that adjusted for age, sex, comorbidities, cancer stage, and functional status. Tumor histology was also adjusted for lung cancer, but not for gastric and colorectal cancer.

^a Comorbidities were measured using the Charlson Comorbidity Index, with 0 points indicating none, 1–2 points indicating moderate comorbidities, and ≥3 points indicating severe comorbidities. ^b Functional status was measured using the Barthel Index, with 100 points indicating no disability, 60–95 points indicating moderate disability, and 0–55 indicating severe disability. aHR, adjusted hazard ratio; CI, confidence interval.